New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
26th May 2023
22nd May 2023
10th May 2023
Colombia: The House of Representatives yesterday approved a bill amending the constitution to enable the consumption and production of recreational cannabis. The bill, which has now been through six debates, will have to go through two more in the Senate before 20th July if it is to be passed.
10th May 2023
Chile: A bill allowing home growing of cannabis for medicinal purposes under prescription, approved in March by both the Chamber of Deputies and the Senate, was signed into law yesterday (9th May) by president Gabriel Boric.
26th April 2023
20th April 2023
Argentina: The Ministry of Health issued a resolution yesterday extending from one year to three the validity of home growers’, patients’ and prescribing doctors’ registration for medical cannabis through the Cannabis Programme Registry (Reprocann).
11th April 2023
Argentina: A regulation further developing Law 27.669, approved in May 2022, to set up a comprehensive regulatory framework for industrial hemp and medical cannabis, has been approved by the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (Ariccame) and the economy minister and will be published in the Official Gazette once the president has approved it, press reports. The regulation will allow licensing of the production, distribution and sale of hemp and hemp extracts, with a maximum allowed THC content of 1%.
3rd April 2023
22nd March 2023
15th March 2023
14th March 2023
Chile: The Chamber of Deputies yesterday approved a report by an inter-house committee that seeks to allow home growing of cannabis for medicinal purposes provided the patient has a doctor’s prescription. The committee, made up of members of both the Senate and the Chamber of Deputies, was set up to agree a common position on a bill already in the legislative process.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.